| Literature DB >> 23646117 |
Tristan Rossignol1, Béla Kocsis, Orsolya Bouquet, Ildikó Kustos, Ferenc Kilár, Adrien Nyul, Péter B Jakus, Kshitij Rajbhandari, László Prókai, Christophe d'Enfert, Tamás Lóránd.
Abstract
We investigated the antifungal activity of fused Mannich ketone (FMK) congeners and two of their aminoalcohol derivatives. In particular, FMKs with five-membered saturated rings were shown to have minimum inhibitory concentration (MIC90s) ranging from 0.8 to 6 µg/mL toward C. albicans and the closely related C. parapsilosis and C. krusei while having reduced efficacy toward C. glabrata and almost no efficacy against Aspergillus sp. Transcript profiling of C. albicans cells exposed for 30 or 60 min to 2-(morpholinomethyl)-1-indanone, a representative FMK with a five-membered saturated ring, revealed a transcriptional response typical of oxidative stress and similar to that of a C. albicans Cap1 transcriptional activator. Consistently, C. albicans lacking the CAP1 gene was hypersensitive to this FMK, while C. albicans strains overexpressing CAP1 had decreased sensitivity to 2-(morpholinomethyl)-1-indanone. Quantitative structure-activity relationship studies revealed a correlation of antifungal potency and the energy of the lowest unoccupied molecular orbital of FMKs and unsaturated Mannich ketones thereby implicating redox cycling-mediated oxidative stress as a mechanism of action. This conclusion was further supported by the loss of antifungal activity upon conversion of representative FMKs to aminoalcohols that were unable to participate in redox cycles.Entities:
Mesh:
Substances:
Year: 2013 PMID: 23646117 PMCID: PMC3639977 DOI: 10.1371/journal.pone.0062142
Source DB: PubMed Journal: PLoS One ISSN: 1932-6203 Impact factor: 3.240
Figure 1Chemical structures of the fused Mannich ketones investigated.
Figure 2Chemical structure of the aminoalcohols investigated.
MIC90s of fused Mannich ketones and aminoalcohols towards Candida, Saccharomyces and Aspergillus species.
| Comp. | MIC90 (µg/mL) | |||||
|
|
|
|
|
|
| |
|
| 3.125 | 6.25 | 3.125 | 1.56 | 0.8 | 100 |
|
| 6.25 | 6.25 | 3.125 | 3.125 | 1.56 | 6.25 |
|
| 0.8 | 6.25 | 3.125 | 3.125 | 1.56 | 50 |
|
| 3.125 | 6.25 | 1.56 | 6.25 | 3.125 | 50 |
|
| 12.5 | 100 | 12.5 | 12.5 | 12.5 | 100 |
|
| 3.125 | 25 | 3.125 | 12.5 | 6.25 | 50 |
|
| 12.5 | 50 | 25 | 12.5 | 25 | 100 |
|
| 6.25 | 12.5 | 3.125 | 6.25 | 6.25 | 50 |
|
| 12.5 | 200 | 25 | 25 | 100 | 50 |
|
| 50 | 200 | 100 | 100 | 50 | 200 |
|
| 25 | 100 | 50 | 50 | 25 | 100 |
|
| 100 | 200 | 200 | 200 | 200 | >200 |
|
| 25 | 100 | 25 | 25 | 12.5 | 200 |
|
| 12.5 | 25 | 25 | 25 | 25 | 50 |
|
| 25 | 50 | 25 | 25 | 6.25 | 25 |
|
| 25 | 50 | 50 | 50 | 25 | 100 |
|
| 6.25 | 50 | 12.5 | 25 | 50 | 100 |
|
| 12.5 | 50 | 50 | 50 | 25 | 200 |
|
| 6.25 | 12.5 | 6.25 | 25 | 6.25 | 50 |
|
| 12.5 | 12.5 | 1.56 | 25 | 3.125 | 100 |
|
| 1.56 | 6.25 | 0.8 | 0.8 | 1.56 | 50 |
|
| >200 | >200 | >200 | >200 | >200 | >200 |
|
| >200 | >200 | >200 | >200 | >200 | >200 |
|
| 0.4 | 0.4 | 0.4 | 0.4 | 0.8 | 3.125 |
Amphotericin B was used as a standard.
QSAR models for antifungal potency of Mannich ketones.a
| Fungal Strain | Best 3-descriptor equation | Best 2-descriptor equation |
|
| pMIC = 2.68* | pMIC = 2.57* |
|
| pMIC = 2.46312* | pMIC = 2.68* |
|
| pMIC = 2.30* | pMIC = 2.17* |
|
| pMIC = 2.43* | pMIC = 2.47* |
|
| pMIC = 2.70* | pMIC = 2.83* |
Includes unsaturated cyclic Mannich ketones and aminoalcohols reported in Kocsis et al. [13].
Figure 3QSAR analysis of Mannich ketones for antifungal activity towards Candida albicans.
Comparison of the experimental and calculated negative logarithms of the minimum inhibitory concentration from QSAR (pMICExp and pMICCalc) of Mannich ketones in C. albicans was based on the equation considering three descriptors: energy of the lowest unoccupied molecular orbital (LUMO, eV) solvent-accessible surface area (SASE, Å2), and ionization potential (IP, eV) (Table 2). Green triangles: Fused Mannich ketones reported here; Magenta squares: unsaturated cyclic Mannich ketones and aminoalcohols reported earlier [13].
Fungal strains used in this study.
| Strains | Species | Description | Genotype | Reference |
| ATCC 90028 |
| Standard strain | ||
| ATCC 3916 |
| Standard strain | ||
| ATCC 30068 |
| Standard strain | ||
| ATCC 22019 |
| Standard strain | ||
| 8897/2000 Pécs |
| Clinical sample | ||
| 10159/2000 Pécs |
| Clinical sample | ||
| SC5314 |
| Sequenced strain |
| |
| CAI4 |
|
|
| |
| BWP17 |
|
|
| |
| CNC13 |
| Deleted for |
|
|
| DSY3410-1 |
| Deleted for | BWP17 |
|
| DSY1691 |
| Deleted for |
|
|
| CJD21 |
| Deleted for |
|
|
| Strains |
| Description |
| Reference |
| CEC3490 |
| Overexpressing |
| This study |
C. albicans genes showing increased expression upon 30 min and 60 min exposure to compound 2.
| Systematic name | Gene name | Ratio 30 min |
| Ratio 60 min |
| Benomyl | Cap1-dependent | H202
| Benomyl | Benomyl Cap1-dependent | Cap1-regulated | Short description | |||||||||
| orf19.113 | CIP1 | 215.4 | 1.07E-03 | 95.99 | 6.54E-06 | ▪ | ▪ | ▪ | ▪ | ▪ | Possible oxidoreductase | ||||||||||
| orf19.3131 | OYE32 | 61.7 | 9.09E-04 | 30.13 | 2.87E-06 | ▪ | ▪ | ▪ | ▪ | ▪ | ▪ | NAD(P)H oxidoreductase family protein | |||||||||
| orf19.5604 | MDR1 | 24.98 | 2.01E-03 | 42.8 | 1.16E-06 | ▪ | ▪ | ▪ | ▪ | Plasma membrane multidrug efflux pump | |||||||||||
| orf19.3139 | 23.76 | 1.36E-04 | 3.842 | 5.47E-08 | ▪ | ▪ | ▪ | ▪ | ▪ | Hap43p-repressed gene | |||||||||||
| orf19.2285 | 17.63 | 4.76E-03 | 14.65 | 3.35E-05 | ▪ | ▪ | ▪ | ▪ | Increased transcription is observed upon benomyl treatment | ||||||||||||
| orf19.251 | 16.43 | 4.27E-08 | 2.994 | 9.48E-06 | ▪ | ▪ | ▪ | ▪ | ▪ | ThiJ/PfpI protein | |||||||||||
| orf19.5285 | PST3 | 15.56 | 9.92E-03 | 6.958 | 1.14E-07 | ▪ | ▪ | Putative flavodoxin | |||||||||||||
| orf19.3443 | OYE2 | 11.7 | 8.98E-04 | 6.748 | 4.21E-07 | ▪ | Putative NAPDH dehydrogenase | ||||||||||||||
| orf19.1149 | MRF1 | 11.42 | 4.92E-03 | 6.223 | 1.56E-07 | ▪ | ▪ | ▪ | ▪ | ▪ | Putative mitochondrial respiratory protein | ||||||||||
| orf19.2262 | 11.28 | 2.38E-03 | 6.234 | 5.68E-10 | ▪ | ▪ | ▪ | ▪ | ▪ | ▪ | Protein similar to quinone oxidoreductases | ||||||||||
| orf19.6898 | 9.273 | 3.03E-03 | 9.889 | 7.11E-10 | ▪ | ▪ | ▪ | ▪ | Predicted ORF | ||||||||||||
| orf19.3121 | GST1 | 9.049 | 1.81E-02 | 1.588 | 4.03E-02 | ▪ | ▪ | ▪ | ▪ | Putative glutathione S-transferase | |||||||||||
| orf19.7042 | 8.096 | 2.48E-03 | 7.62 | 1.99E-03 | ▪ | ▪ | ▪ | ▪ | Increased transcription is observed upon benomyl treatment | ||||||||||||
| orf19.1763 | IFR1 | 6.616 | 2.78E-02 | 3.001 | 1.08E-04 | ▪ | ▪ | ▪ | ▪ | Predicted ORF | |||||||||||
| orf19.5286 | YCP4 | 6.288 | 6.19E-03 | 3.602 | 4.10E-06 | Putative flavodoxin | |||||||||||||||
| orf19.2396 | IFR2 | 5.712 | 1.06E-04 | 3.128 | 2.11E-07 | ▪ | ▪ | ▪ | ▪ | ▪ | ▪ | Zinc-binding dehydrogenase | |||||||||
| orf19.5517 | 5.633 | 1.67E-04 | 1.952 | 4.42E-06 | ▪ | ▪ | ▪ | ▪ | ▪ | ▪ | Similar to alcohol dehydrogenases | ||||||||||
| orf19.7306 | 5.539 | 3.30E-02 | 3.896 | 1.62E-06 | ▪ | ▪ | Aldo-keto reductase family protein | ||||||||||||||
| orf19.847 | YIM1 | 5.318 | 5.94E-04 | 2.895 | 3.70E-05 | ▪ | ▪ | ▪ | ▪ | Protein similar to protease of mitochondrial inner membrane | |||||||||||
| orf19.1340 | 5.312 | 4.93E-05 | 1.582 | 1.38E-03 | ▪ | ▪ | Putative aldose reductase | ||||||||||||||
| orf19.1237 | ARO9 | 5.082 | 2.22E-02 | 2.141 | 1.98E-04 | ▪ | Aromatic transaminase of the Ehrlich fusel oil pathway of aromatic alcohol biosynthesis | ||||||||||||||
| orf19.3150 | GRE2 | 5.012 | 4.43E-03 | 3.405 | 3.53E-06 | ▪ | ▪ | ▪ | Putative reductase; benomyl- induced | ||||||||||||
| orf19.7531 | 4.633 | 1.87E-02 | 2.131 | 1.26E-06 | ▪ | ▪ | Putative protein of unknown function | ||||||||||||||
| orf19.2693 | GST2 | 4.453 | 1.16E-03 | 3.151 | 8.04E-06 | ▪ | ▪ | ▪ | Putative glutathione S transferase | ||||||||||||
| orf19.1048 | IFD6 | 3.835 | 7.52E-03 | 2.548 | 1.73E-02 | ▪ | ▪ | Aldo-keto reductase family member | |||||||||||||
| orf19.1868 | RNR22 | 3.83 | 4.09E-02 | 1.825 | 3.42E-02 | ▪ | ▪ | Putative ribonucleoside diphosphate reductase | |||||||||||||
| orf19.3234 | OYE22 | 3.777 | 2.30E-02 | 1.713 | 7.88E-04 | ▪ | ▪ | ▪ | Putative NADPH dehydrogenase | ||||||||||||
| orf19.3122 | ARR3 | 3.609 | 1.75E-06 | 2.951 | 1.19E-08 | ▪ | ▪ | ▪ | ▪ | ▪ | Protein not essential for viability | ||||||||||
| orf19.4309 | GRP2 | 3.59 | 4.39E-03 | 1.756 | 6.74E-07 | ▪ | ▪ | ▪ | ▪ | ▪ | Methylglyoxal reductase | ||||||||||
| orf19.1167 | 3.29 | 4.06E-02 | 2.175 | 8.90E-03 | ▪ |
| |||||||||||||||
| orf19.1162 | 3.22 | 1.09E-02 | 2.398 | 8.66E-07 | ▪ | ▪ | ▪ | Predicted ORF | |||||||||||||
| orf19.7611 | TRX1 | 3.179 | 2.38E-03 | 1.543 | 5.88E-05 | ▪ | ▪ | Thioredoxin, involved in response to reactive oxygen species | |||||||||||||
| orf19.6586 | 3.138 | 3.50E-02 | 2.88 | 3.02E-05 | ▪ | ▪ | ▪ | ▪ | Late-stage biofilm-induced gene | ||||||||||||
| orf19.2500 | 2.998 | 2.26E-03 | 1.625 | 3.08E-04 | |||||||||||||||||
| orf19.6059 | TTR1 | 2.908 | 1.00E-03 | 2.024 | 1.51E-04 | ▪ | ▪ | ▪ | ▪ | Putative glutaredoxin | |||||||||||
| orf19.2461 | PRN4 | 2.8 | 4.61E-03 | 2.263 | 5.67E-06 | ▪ | ▪ | Protein with similarity to pirins | |||||||||||||
| orf19.4449 | 2.766 | 4.93E-03 | 1.655 | 3.31E-03 | ▪ | ▪ | ▪ |
| |||||||||||||
| orf19.1027 | PDR16 | 2.456 | 4.71E-02 | 2.278 | 2.58E-05 | ▪ | Phosphatidylinositol transfer protein | ||||||||||||||
| orf19.2369.1 | ATX1 | 2.389 | 3.37E-03 | 1.608 | 1.63E-04 | ▪ | Putative cytosolic copper metallochaperone | ||||||||||||||
| orf19.2825 | 2.356 | 7.77E-05 | 1.822 | 4.46E-05 | ▪ | Putative cytosolic Fe-S protein assembly protein | |||||||||||||||
| orf19.2862 | RIB1 | 2.216 | 1.16E-04 | 1.653 | 1.22E-04 | ▪ | ▪ | ▪ | Putative GTP cyclohydrolase II; enzyme of riboflavin biosynthesis | ||||||||||||
| orf19.5258 | 2.156 | 4.63E-03 | 1.681 | 1.05E-04 | ▪ | ▪ | Predicted ORF | ||||||||||||||
| orf19.1623 | CAP1 | 2.11 | 6.74E-04 | 1.738 | 2.30E-04 | ▪ | ▪ | ▪ | ▪ | Transcription factor, AP-1 bZIP family; role in oxidative stress response | |||||||||||
| orf19.2202 | 2.093 | 4.55E-02 | 1.508 | 2.51E-02 | ▪ | Predicted ORF | |||||||||||||||
| orf19.2463 | PRN2 | 1.993 | 6.57E-03 | 1.851 | 1.93E-04 | ▪ | Protein similar to pirin; Hap43p-repressed gene | ||||||||||||||
| orf19.5860 | 1.984 | 4.95E-02 | 1.792 | 9.01E-04 | Predicted ORF | ||||||||||||||||
| orf19.5784 | AMO1 | 1.911 | 1.16E-02 | 1.699 | 3.29E-05 | Putative peroxisomal copper amine oxidase | |||||||||||||||
| orf19.344 | 1.885 | 1.46E-04 | 1.803 | 1.80E-02 | ▪ | ▪ | ▪ | Predicted ORF | |||||||||||||
| orf19.1724 | 1.878 | 2.09E-03 | 1.975 | 9.36E-06 | Protein of unknown function | ||||||||||||||||
| orf19.6478 | YCF1 | 1.861 | 3.96E-03 | 1.648 | 8.07E-05 | ▪ | ▪ | ▪ | Putative glutathione S-conjugate transporter | ||||||||||||
| orf19.3448 | 1.812 | 1.08E-02 | 1.528 | 2.59E-04 | Predicted ORF | ||||||||||||||||
| orf19.3130 | 1.762 | 4.42E-03 | 1.883 | 1.18E-05 | ▪ | ▪ | Predicted ORF | ||||||||||||||
| orf19.5282 | 1.73 | 4.96E-04 | 1.527 | 8.35E-03 | ▪ | Hap43p-repressed gene | |||||||||||||||
| orf19.2462 | PRN3 | 1.555 | 2.49E-02 | 1.972 | 4.43E-05 | ▪ | ▪ | Protein similar to pirin | |||||||||||||
| orf19.3395 | 1.544 | 6.52E-03 | 1.615 | 2.89E-02 | ▪ | ▪ | ▪ | ▪ | Predicted membrane transporter | ||||||||||||
| orf19.4757 | NAR1 | 1.518 | 3.72E-03 | 1.851 | 1.02E-03 | ▪ | ▪ | ▪ | Putative cytosolic iron-sulfur (FeS) protein | ||||||||||||
Annotated as benomyl regulated in CGD database.
Annotated as Cap1 dependent regulation in CGD database.
Induced by H2O2 according to Wang et al. [25].
Induced by Benomyl according to Znaidi et al. [26].
Induced by benomyl in a Cap1 dependent manner according to Znaidi et al. [26].
Direct target of Cap1 according to Znaidi et al. [26].
Figure 4Growth kinetics in 96-well microtiter plates of C. albicans strains exposed to various concentrations of compound 2.
A. Representative growth kinetics of BWP17 and cap1Δ/Δ strains exposed to decreasing concentrations of compound 2 in SD minimal medium. B. Representative growth kinetics of BWP17, cap1Δ/Δ and CAP1 overexpression strains in inducible medium (YNB-casa) exposed to 12.5 µg/mL compound 2. C. Representative growth kinetics of several transcription factor mutants and parent strains in SD minimal medium exposed to 6.25 µg/mL compound 2.